Saxagliptin and risk of heart failure hospitalization: Concern or miscalculation?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Saxagliptin and risk of heart failure hospitalization: Concern or miscalculation?

Published:2016-10 Issue: Volume:220 Page:573-574
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Cebrián-Cuenca Ana María,Orozco-Beltrán Domingo,Navarro-Pérez Jorge,Franch-Nadal Josep,Núñez-Villota Julio,Consuegra-Sánchez Luciano

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference6 articles.

1. Statistical controversies in reporting of clinical trials: part 2 of a 4-part series on statistics for clinical trials;Pocock;J. Am. Coll. Cardiol.,2015

2. SAVOR-TIMI 53 steering committee and investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus;Scirica;N. Engl. J. Med.,2013

3. SAVOR-TIMI 53 steering committee and investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial;Scirica;Circulation,2014

4. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study;Scirica;Am. Heart J.,2011

5. Gliptins and cardiovascular outcomes: a comparative and critical analysis after TECOS;Ghosal;J. Diabetes. Res.,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The safety of gliptins : updated data in 2018;Expert Opinion on Drug Safety;2018-03-03

2. Saxagliptina e insuficiencia cardiaca en el estudio SAVOR-TIMI 53: bajo la lupa de Bradford Hill;Revista Española de Cardiología;2017-12

3. Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria;Revista Española de Cardiología (English Edition);2017-12

4. Cardio Vascular Outcomes Trials (CVOTs) with Anti-Hyperglycemic Agents: Demystifying Statistical Complexities;Journal of Diabetes, Metabolic Disorders & Control;2017-06-21

5. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry;Diabetes, Obesity and Metabolism;2017-05-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3